Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Marc Braunstein

Myeloma · NYU Grossman Long Island

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    SADr. Shebli Atrash

    Dr. Shebli Atrash

    Hematology & Oncology · Myeloma
    Atrium Health Wake Forest Baptist
    shebli

    Research

    Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis

    2026

    Via Cancers

    Research

    Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study

    2026

    Via European Journal of Haematology

    Research

    BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment

    2026

    Via Current Oncology

    Research

    A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group

    2026

    Via Cancers

    Research

    Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis

    2026

    Via Current Oncology

    Research

    Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation

    2026

    Via Blood Neoplasia

    Research

    The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma

    2026

    Via American Journal of Hematology

    Research

    Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients

    2026

    Via Current Oncology

    Research

    High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis

    2026

    Via Current Oncology

    Research

    Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma

    2026

    Via Blood Advances

    Research

    Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma

    2026

    Via European Journal of Haematology

    Research

    From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma

    2026

    Via Expert Review of Hematology

    Research

    Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC

    2026

    Via Current Oncology

    Research

    Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

    2026

    Via American Journal of Hematology

    Research

    The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis

    2026

    Via Current Oncology